Market Place
Sourcing Support
All News #Library
Biotech
Viking Therapeutics Completes VK2735 Phase 3 VANQUISH-2 Trial
26 Mar 2026 //
PR NEWSWIRE
Viking Therapeutics Announces VK2735 Phase 2 Obesity Results
12 Jan 2026 //
PR NEWSWIRE
Viking Therapeutics Completes VK2735 Maintenance Dosing Trial
08 Jan 2026 //
PR NEWSWIRE
Viking Therapeutics at 44th J.P. Morgan Healthcare Conference
05 Jan 2026 //
PR NEWSWIRE
Viking Therapeutics Completes Enrollment In VK2735 Phase 3 Trial
19 Nov 2025 //
PR NEWSWIRE
Viking Therapeutics Showcases VK2735 Obesity Program Data
06 Nov 2025 //
PR NEWSWIRE
Viking Therapeutics To Present At Investor Conferences
05 Nov 2025 //
PR NEWSWIRE
Viking Therapeutics Showcases VK2735 Obesity Program Data
30 Oct 2025 //
PR NEWSWIRE
Viking Therapeutics Starts VK2735 Maintenance Dosing Trial
21 Oct 2025 //
PR NEWSWIRE
Viking Therapeutics to Present at Investor Conferences
28 Aug 2025 //
PR NEWSWIRE
Lilly, Viking Data Reset Oral Weight-Loss Race
26 Aug 2025 //
BIOSPACE
Novo Leads as Oral Obesity Candidates Disappoint
22 Aug 2025 //
BIOSPACE
Viking Therapeutics Reports Q2 2025 Financials, Updates
23 Jul 2025 //
PR NEWSWIRE
Viking Therapeutics Completes Enrollment in Phase 2 Oral Trial
26 Mar 2025 //
PR NEWSWIRE
Viking Starts Phase 2 Trial of VK2735 Tablet for Obesity Patients
08 Jan 2025 //
PR NEWSWIRE
Viking Therapeutics Reports VK2735 Data at ObesityWeek® 2024
04 Nov 2024 //
PR NEWSWIRE
Viking Therapeutics Highlights VK2735 Data at ObesityWeek® 2024
28 Oct 2024 //
PR NEWSWIRE
Viking Announces Completion of Enrollment in Ph 2 Trial of Dual GLP-1/GIP VK2735
23 Oct 2023 //
PR NEWSWIRE
Viking Announces Initiation of Phase 2 Trial of Dual GLP-1/GIP Receptor VK2735
06 Sep 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.